Safety, tolerability and pharmacokinetics of BI 409306, a potent and selective phosphodiesterase 9A inhibitor, were assessed in healthy subjects in three Phase I, within-dose group, double-blind trials. Trial 1 randomised young and elderly subjects to receive BI 409306 25, 50, 100 mg, placebo once daily (OD) or BI 409306 50 mg twice daily (young) for 14 days. Trial 2 randomised young poor metabolisers (PM) of cytochrome P450 isoform 2C19 (CYP2C19) and elderly subjects to receive BI 409306 25, 50 mg or placebo OD for 14 days. Trial 3 randomised Chinese and Japanese extensive metabolisers of CYP2C19 to receive single doses (SD) of BI 409306 25, 50, 100 mg or placebo and Chinese (PM) to SD of BI 409306 100 mg or placebo (Part 1). Japanese PM received SD of BI 409306 100 mg or placebo (Day 1) followed by BI 409306 100 mg or placebo OD for 7 days after a 48-hour washout period (Part 2). Reported adverse events (AE) were mild-to-moderate intensity and increased with BI 409306 dose. Eye disorders were most commonly reported (Trial 1: 40.0-41.7%, Trial 2: 29.2-37.5%, Trial 3: 18.2-66.7%) and increased with dose and systemic exposure. PM reported more AEs than other treatment groups, corresponding to higher systemic exposure to BI 409306. Systemic exposure to BI 409306 produced dose-dependent increases and was slightly www.elsevier.com/locate/euroneuro
Introduction
One of the key characteristics of schizophrenia and Alzheimer's disease (AD) is an abnormality in glutamatergic neurotransmission related to N-methyl-D-aspartate (NMDA) receptor hypofunction in cortical and hippocampal brain areas. (Lee et al., 2002; Lewis and Moghaddam, 2006; Stephan et al., 2009 ) NMDA receptor activation produces postsynaptic signalling events through elevation of second messengers such as cyclic guanosine monophosphate (cGMP). (Bales et al., 2010) In conditions of NMDA receptor hypofunction, it has been hypothesised that inhibition of phosphodiesterase 9A (PDE9A), which hydrolyses cGMP, may increase cGMP levels and improve NMDA receptor signalling. This would lead to strengthened synaptic plasticity and stabilisation, as determined by enhanced long-term potentiation (LTP), and thus improving cognitive function ( Figure S1 ). (Bales et al., 2010; Cooke and Bliss, 2006; Rezvani, 2006; Moschetti et al., 2016; DornerCiossek et al., 2017) .
This hypothesis has been supported by results from animal models of cognitive impairment, using the novel PDE9A inhibitor BI 409306. In rodents, BI 409306 was shown to be a potent and selective PDE9A inhibitor, which induced a dose-dependent increase in cGMP levels in the pre-frontal cortex and cerebrospinal fluid (CSF), reversed dizocilpineinduced memory deficits in the T-maze continuous alternation task and improved memory performance in the object recognition task. Dorner-Ciossek et al., 2015) .
In a first-in-human trial, single doses (SD) of BI 409306 r350 mg showed an acceptable safety and tolerability profile for young, healthy males genotyped as extensive metabolisers (EM) of cytochrome P450 isoform 2C19 (CYP2C19) and for males genotyped as poor metabolisers (PM) of CYP2C19 at doses of 10 and 100 mg. (Moschetti et al., 2016) . CYP2C19 is an enzyme involved in oxidative metabolism of BI 409306. The absorption and elimination of BI 409306 was rapid, and plasma concentrations increased with the dosage. Males with two non-functional alleles of CYP2C19 (PM) displayed higher exposure compared with EM carrying two functional alleles of CYP2C19: the maximum measured concentration in the plasma (C max ) was 2.2-to 2.3-fold higher, and the area under the concentration-time curve of the analyte in plasma from time 0 extrapolated to infinity (AUC 0-1 ) was 4.1-to 5.0-fold higher after a single dose. The reported adverse events (AEs) were mild to moderate in intensity and mostly related to nervous system or eye disorders and were resolved within 2 hours. (Moschetti et al., 2016) .
In addition, results from a proof-of-clinical-mechanism trial in healthy males showed that SD of BI 409306 25-200 mg were rapidly absorbed in plasma and distributed in CSF. This pattern of absorption subsequently resulted in a dose-dependent increase in concentrations of cGMP within the CSF, indicating functional target engagement. (Boland et al., 2017) .
Following on from the first-in-human and proof-ofmechanism trials, where single doses were applied, the intention of this publication is to provide an overview of safety, tolerability and pharmacokinetic (PK) data from three Phase I trials where repeat doses of BI 409306 were administered to healthy subjects. These trials include subjects who were young and elderly, of Caucasian and Asian ethnicities and genotyped for CYP2C19.
Experimental procedures 2.1. Trial designs
The three trials were randomised (BI 409306 3:1 placebo), placebocontrolled and double-blinded within-dose groups, single-centre trials. The primary objective of each trial was to establish the safety and PK for SD and multiple doses (MD) of BI 409306 in selected populations.
All three trials were approved by an institutional review board/independent ethics committee and competent authority and conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (GCP) guidelines (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996) , the Japanese GCP regulations (Ordinance of the Ministry of Health and Welfare, 2011) , and the Declaration of Helsinki.(World Medical Association, 2013) All subjects provided written, informed consent prior to participation.
Subjects
In Trials 1 (NCT01505894) and 2 (NCT01611311) conducted in Germany, subjects were healthy volunteers of either 21-50 years of age (young subgroup) or 65-80 years of age (elderly subgroup), with a body mass index (BMI) of 18.5-29.9 kg/m 2 . In Trial 2 the healthy young subjects were prospectively genotyped as homozygous for CYP2C19 PM (definition included in 
Treatments
In Trial 1, young and elderly subjects were randomised to receive BI 409306 25, 50 or 100 mg once daily (OD), BI 409306 50 mg twice daily (BID) (young subgroup) or placebo for 14 days. In Trial 2, young CYP2C19 PM and elderly subjects were randomised to receive BI 409306 25, 50 mg or placebo OD for 14 days. In Part 1 of Trial 3, Chinese and Japanese subjects genotyped as CYP2C19 EM were randomised to receive a SD of BI 409306 25, 50 or 100 mg or placebo and Chinese subjects genotyped as CYP2C19 PM were randomised to receive SD of BI 409306 100 mg or placebo. In Part 2 of Trial 3 (after a 48-hour washout period), subjects in the Japanese CYP2C19 PM subgroup received a SD of BI 409306 100 mg or placebo on Day 1 followed by 7 days of BI 409306 100 mg or placebo OD. In all trials, BI 409306 was administered as a film-coated tablet, which was given orally after an overnight fast of at least 10 hours.
Endpoints
2.4.1. Safety Safety and tolerability were assessed descriptively based on AEs, including the number (%) of subjects with drug-related AEs, physical examination, vital signs, 12-lead ECG, clinical laboratory tests, a colour discrimination test (Ishihara test), a visual acuity test (Snellen chart), and ophthalmological examination (including fundus photography). Global tolerability was assessed by the investigator. In addition, a suicidality assessment was conducted using the Columbia Suicide Severity Rating Scale (C-SSRS). (Posner et al., 2011) Eye disorders were monitored closely throughout the three trials, based on findings from the first-in-human SD trial. (Moschetti et al., 2016) .
PK
The following key PK endpoints were determined for BI 409306 from plasma concentration time profiles obtained at steady state (SS) after last dosing, in patients who had received MD: C max,ss , time from dosing until C max,ss (t max,ss ); terminal half-life (t 1/2,ss ); the accumulation ratio of the analyte in plasma at SS, corresponding to the ratio of C max,ss to C max after the first dose, (R A,Cmax ); and the accumulation ratio of the analyte in plasma at SS, corresponding to the ratio of area under the concentration-time curve of the analyte in plasma at SS over a uniform dosing interval τ (AUC τ,ss ) to either the area under the concentration-time curve of the analyte in plasma over the time interval 0 to 12 hours (AUC 0-12 ) after the first dose for the treatment groups with BID dosing or to the area under the concentration-time curve of the analyte in plasma over the time interval 0 to 24 hours (AUC 0-24 ) after the first dose for the treatment groups with OD dosing (R A,AUC ). These endpoints were compared with PK endpoints obtained after the first dose. In addition, corresponding PK endpoints after SD were derived.
The plasma concentration of BI 409306 was determined by using a validated liquid chromatography, tandem mass spectrometry assay, with [ 13 C 2 , D 4 ]-BI 409306 as the internal standard (limit of quantification [LOQ] : 0.100 nM/L; imprecision at LOQ: CV of 6.4%). Blood samples were taken pre-dose every day and at 10 minutes, 20 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours and 14 hours post dose on Day 1, and after last dosing on Day 7 (Part 2 of Trial 3) or Day 14 (Trials 1 and 2 only). In Trials 1 and 2, additional samples were collected before the first dose on Days 2-13, in the morning on Days 15, 16 and 17 (for OD and BID doses), and before the second dose on Days 12 and 13 (for BID doses). In Trial 3, additional samples were collected post dose on Days 2-6, and on Days 8 and 9 (Part 2).
Analyses
The Treated Set (TS) population, defined as all subjects who received at least one dose of the trial medication, was used to assess safety, tolerability, demographics and baseline characteristics. The PK Set (PKS) population, defined as all subjects in the treated set with at least one evaluable observation for a PK endpoint and without important protocol violation relevant to the evaluation of PK, was used for PK analyses. Safety, tolerability and PK parameters were evaluated descriptively in all trials.
For all trials, the sample sizes were considered sufficient for the exploratory evaluation of safety and PK. In Trial 1, a sample size of 48 young and 36 elderly healthy subjects enabled 12 subjects per dose group (9 on active treatment and 3 on placebo). In Trial 2, a sample size of 16 young healthy CYP2C19 PM enabled 8 subjects per dose group (6 on active treatment and 2 on placebo). There were 24 elderly subjects that were divided into 12 subjects per dose group (9 on active treatment and 3 on placebo). In Trial 3, a sample size of 64 healthy Asian male subjects (32 Chinese and 32 Japanese), allowed for 8 subjects per treatment group (6 on active treatment and 2 on placebo). Carrier of one wild-type allele (*1) and one non-functional allele (*2 or *3) Poor metaboliser
Carrier of two non-functional alleles (*2 or *3) Ultra-rapid metaboliser Carrier of two alleles with elevated activity/expression (*17) or carrier of one allele with elevated activity and one wild-type allele
The wild-type allele *1 is defined by absence of other tested alleles; tested alleles in Trial 1 were *2, *3, *4, *5, *8, *9 and *17; tested alleles in Trials 2 and 3 were *2, *3 and *17. For allele definition see (The Human Cytochrome P450 (CYP) Allele Nomenclature Database).
Results

Subject demographics and baseline characteristics
Subject disposition is summarised in Table S1 . Overall, 46/ 48 subjects in the young subgroup and all (35/35) subjects in the elderly subgroup completed Trial 1. In Trial 2, all 16 subjects in the young CYP2C19 PM subgroup and all 24 subjects in the elderly subgroup completed the trial. In Trial 3, 62/65 (32 Chinese and 30 Japanese) subjects were treated and completed the trial (Table S1 ). Baseline subject demographics and characteristics are summarised in Table S2 . Briefly, in Trials 1 and 2, subjects in the young subgroup were mostly male with mean ages of 42 and 30.5 years, respectively. In Trial 1, the majority of subjects in the young subgroup were Caucasian (97.9%) while in Trial 2, the majority were Asian (87.5%). Subjects in the elderly subgroup in Trial 1 were mostly female (60%) and all were Caucasian, with a mean age of 68.7 years, while the elderly subgroup in Trial 2 included mostly male (54.2%) subjects with a mean age of 69.5 years old and all were Caucasian. In Trial 3, all subjects were of Asian ethnicity and male, with a mean age of 26.4 years (Table S2) .
In Trial 1, most subjects in the young subgroup were CYP2C19 EM (EM: 25, IM: 7, PM: 1, UM: 15) compared with the elderly subgroup, which were mostly CYP2C19 UM (EM: 10, IM: 7, PM: 3, UM: 15). In Trial 2, all subjects in the young subgroup were CYP2C19 PM whereas the elderly subgroup were mainly CYP2C19 EM (EM: 10, IM: 3, PM: 0, UM: 7). For three subjects, genotyping analysis eliminated the PM allele, but the UM allele could not be determined; these subjects were therefore classified as CYP2C19 EM. Trial 3 included 46 subjects with a CYP2C19 EM phenotype and 16 subjects with a CYP2C19 PM phenotype.
Safety overview
After MD administration, AEs were reported by 31 (64.6%) young and 22 (62.9%) elderly subjects in Trial 1, 9 (56.3%) young and 14 (58.3%) elderly subjects in Trial 2 and 15 (46.9%) of subjects in Trial 3. Across the trials, the majority of AEs were of mild intensity. The most commonly reported AE categories were eye disorders (a predefined AE category of interest) and nervous system disorders including headache, dizziness and somnolence (Tables S3-S5) . Specifically, subjects experiencing eye disorders reported transient symptoms of photopsia (flashing lights), photophobia (increased sensitivity to light), chromatopsia (change in colour perception) and blurred vision, which were of mild intensity, short duration and occurred shortly after administration. The frequency of eye disorders, but neither their maximum duration nor their intensity, increased with the BI 409306 dose. Some subjects reported eye disorders on almost all treatment days without signs of habituation or adaptation. However, the general ophthalmological examinations did not reveal any permanent visual changes or evidence of macular degeneration, and most visual disorders were not accompanied by findings in the visual tests. Across the trials, only two subjects reported visual impairment as an AE. In Trial 1, one subject in the young subgroup receiving 50 mg BID was unable to read all numbers from the presented Ishihara colour plates on Day 2 and one subject in the elderly subgroup receiving 100 mg OD could not read the smallest font from the Snellen chart on Day 3, which the subject had been able to read at screening. For AEs considered by the investigator to be related to the trial drug, there was a higher frequency observed in the BI 409306 100 mg dose groups compared with lower dose groups, but there were no dose-dependent trends in either the maximum duration or the intensity. There were no reported serious AEs, severe AEs or protocolspecified significant AEs. There were two clinically significant findings of elevated liver enzymes reported as AEs for one subject in the young subgroup receiving placebo (which led to discontinuation), and one subject in the elderly subgroup receiving BI 409306 50 mg in Trial 1. In Trial 2, one subject in the elderly subgroup receiving BI 409306 50 mg and one subject in the young CYP219C PM subgroup receiving BI 409306 25 mg reported elevated liver enzymes, but neither met the protocol criterion for significant AEs. For an additional CYP2C19 PM treated with placebo, a mild AE of atrioventricular block second degree was reported, which was likely to have been a vagal reaction in Trial 2. In Trial 3, a CYP2C19 PM treated with BI 409306 100 mg reported a slight increase in heart rate of 12.9 7 4.4 and 9.4 72.6 bpm at 20 and 30 minutes posttreatment.
There were no other clinically relevant findings from ECG recordings (including QT/QTc intervals evaluation), vital sign measurements (including orthostatic testing), physical examinations or clinical laboratory assessments in the BI 409306-treated groups. Across the trials, there were no reports of suicidal ideation or behaviour and no reported deaths. Safety data for SD administration are presented in Table 2 and were similar to data reported for MD administration.
Age-related differences
In Trial 1, the young and elderly subgroups reported a similar number of AEs (young: n =31 [64.6%]; elderly: n = 22 [62.9%]) (Table 3) , as did the elderly subgroup in Trial 2 (n= 14 [58.3%]) subjects (Table 4 ). The number of AEs considered related to the trial drug was also similar in the young and elderly subgroups in Trial 1 (young: n =24 [50%], elderly: n = 17 [48.6%]). Of the drug-related AEs, the most commonly reported were eye disorders. Again, the incidences of these were similar in the young and elderly subgroups (Trial 1, young: n= 18 [37.5%], Trial 1, elderly: n = 14 [40.0%], Trial 2, elderly: n= 6 [25.0%]).
In the young subgroup of Trial 1, drug-related eye disorders were reported by 2 (16.7%) subjects receiving placebo and 16 (44.4%) subjects receiving BI 409306 compared with 1 (11.1%) receiving placebo and 13 (50.0%) receiving BI 409306 in the elderly subgroup. In Trial 2, 6 (37.5%) subjects in the young subgroup reported drugrelated eye disorders, with 1 (25.0%) subject receiving placebo and 5 (41.7%) subjects receiving BI 409306. In the elderly subgroup, 2 (33.3%) subjects receiving placebo and 4 (22.2%) receiving BI 409306 reported drug-related eye disorders. It is worth mentioning that 4 subjects in the elderly subgroup receiving BI 409306 reported photophobia and 3 reported chromatopsia, with 2 subjects reporting these symptoms after receiving the fourth and ninth dose, respectively. The remaining 2 subjects reported the first occurrence of chromatopsia and photophobia during the first 8 doses, and the last event during doses 12 to 14. Overall, the frequency of photopsia, vision blurred, chromatopsia and photophobia appeared to increase with increasing dose of BI 409306. All eye disorders in both the young and elderly subgroups were of mild-to-moderate intensity, and occurred within 2 hours of dosing. For BI 409306 treatment groups, the mean maximum duration of eye disorders was similar in both young and elderly subgroups, with resolution occurring within 1.4 hours in the BI 409306 treatment groups and within 2.8 hours in placebo groups.
As with all-cause AEs, nervous system disorders, including dizziness and headache were the second most commonly reported drug-related AEs in young and elderly subgroups. In Trial 1, dizziness was more prevalent in the elderly subgroup compared with the younger subgroup (n = 4 [11.4%] vs n= 1 [2.1%]) and vice versa for headache (n = 3 [8.6%] vs n= 6 [12.5%]) (Tables 3 and 4). In Trial 2, dizziness (n = 5 [20.8%]) and orthostatic intolerance (changes in blood pressure with or without increase in a heart rate and not accompanied by any clinical symptoms; n = 5 [20.8%]) were the most frequently reported drug-related AEs in elderly subjects.
CYP2C19 phenotype
Overall, there was a greater proportion of AEs and drugrelated AEs in the CYP2C19 PM subgroup compared with other treatment groups that were not stratified for CYP2C19 (Tables 2-4) . In Trial 2, AEs and drug-related AEs in the young CYP2C19 PM subgroup appeared to increase in a dosedependent manner (Table 3) . In Trial 3, 5 (83.3%) subjects in the Japanese CYP2C19 PM subgroup reported AEs after receiving the higher dose (100 mg MD) of BI 409306 (Table 4 ). The most commonly reported drug-related AEs in the CYP2C19 PM subgroups were also eye disorders. In Trial 2, 5 (41.7%) subjects in the young CYP2C19 PM subgroup receiving BI 409306 reported at least one episode of photophobia, with 1 (8.3%) subject also reporting chromatopsia. These symptoms first occurred either after the first dose (n =4 [33.3%]) or the third dose (n = 1 [8.3%]). In Trial 3, 4 (66.7%) subjects in the Japanese CYP2C19 PM subgroup receiving BI 409306 100 mg MD reported 33 episodes of eye disorders (photopsia, chromatopsia, asthenopia, photophobia, eye pain and visual impairment) (Table 4) , compared with no subjects receiving placebo. In both trials, symptoms started in less than 1 hour of receiving the first dose of BI 409306 and spontaneously resolved within 1.5 hours. Nervous system disorders were the second most commonly reported AE in CYP2C19 PM subgroups in Trials 2 and 3, including dizziness (both trials), headache (Trial 3, Part 2) and somnolence (Trial 2).
PK overview
PK data, reported in Trials 3, 1 and 2 are shown in Tables 2-4, respectively. The SS PK profile of BI 409306 was characterised by rapid absorption with median t max consistently less than 1 hour, followed by a rapid monophasic to biphasic elimination. Plasma concentrations peaked 15-90 minutes after administration, and usually fell below the limit of quantification before the next daily dose was administered ( Figure 1A-C) . Across the trials, the total and maximum systemic exposure to BI 409306 increased with dose (Tables 2-4 and  Supplemental Tables S6-S9) . No apparent deviation from dose proportionality was observed. SS was achieved by Day 2-3 and accumulation was low after MD. Across the three trials, mean accumulation ratios for AUC (R A,AUC ) ranged from 0.964 to 1.41 in dose groups which included mostly non-PM of CYP2C19 and from 1.14 to 1.37 in dose groups that included CYP2C19 PM only (Table S6 -S8). The PK results from Day 1 were similar to those at SS.
Young versus elderly
Systemic exposure in young and elderly subjects was primarily compared in Trial 1, which included Caucasian subjects not stratified by CYP2C19 genotype. In this trial, peak plasma levels and total exposure to BI 409306 at SS (C max,ss and AUC τ,ss , respectively) tended to be higher in the elderly subgroups compared with the young subgroups across all doses (Table 3 and S9). The exposure in elderly was similar in Trial 2, where elderly Caucasians not stratified for CYP2C19 genotype were also included. Accumulation (R A,AUC ) and t 1/2,ss was similar across doses and age groups upon multiple dosing (Tables 3 and 4 and S6, S7 and S8).
3.3.2. CYP2C19 phenotype BI 409306 is extensively metabolised, predominantly via CYP2C19 and consequently systemic exposure to BI 409306 was generally higher in subjects with a predicted PM phenotype compared with other predicted CYP2C19 phenotypes; across trials and dose groups.
Accumulation upon multiple dosing in PM was evaluated in particular in Trial 2 (25 and 50 mg OD) and Trial 3 (Japanese, 100 mg OD). Overall, the t 1/2,ss was similar in both the dose groups not stratified for CYP2C19 (1.62-3.55 hours) and in the young CYP2C19 PM subgroup in Trial 2 (2.15-4.10 hours), and in the Japanese CYP2C19 PM subgroup (Part 2, Trial 3) (4.86 hours). The t max,ss was similar across dose groups in CYP2C19 PMs. SS was achieved by Day 3 and accumulation was minor.
The exposure of subjects with a predicted IM, EM and UM phenotype fell within a similar range based on exploratory graphical comparison of available data obtained in Trial 1 and 2 (data not shown).
Discussion
The three Phase I trials described here evaluated the safety, tolerability and PK of MD of BI 409306 in healthy subjects that were young and elderly, of Caucasian and Asian ethnicity and genotyped as CYP2C19 PM, EM, IM or UM. The purpose of this report is to provide an overview of the existing data collected after MD to identify any important trends and consolidate learning to date. Table 3 AEs and PK response, Trial 1. AE data: Frequency, n (%) of subjects with investigator-defined drug-related AEs by treatment group, primary system organ class and preferred term occurring in Z2% of patients in Trial 1. PK data: Data provided as gMean (% gCV) unless stated otherwise. Please note that a subject may be counted in more than one seriousness criterion. AE, adverse event; AUC τ,ss , area under the concentration-time curve of BI 409306 in plasma at SS over a uniform dosing interval τ; BD, (twice daily); C max,ss , maximum measured concentration of BI 409306 in plasma at SS; gCV, geometric coefficient of variation; gMean, geometric mean; N, number of subjects; SD single dose; SS, steady state; t 1/2,ss terminal halflife of BI 409306 in plasma at SS; t max,ss , time from last dosing until the maximum concentration of BI 409306 in plasma is reached at SS a The investigator assessed the possible causal relationship between an AE and the trial medication; b Reported as median (minimum-maximum).
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The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor shortly after subjects received BI 409306 in Trial 3 was not noted in any other group, irrespective of age, CYP2C19 phenotype or dose. Overall, age did not impact on the frequency of AEs, whereas there was a greater proportion of AEs in the CYP2C19 PM subgroups compared with other treatment groups that were not stratified for CYP2C19. As systemic exposure of BI 409306 in the CYP2C19 PM subgroup was higher compared with other treatment groups, this may account for the higher frequency of AEs observed in this group. An additional indication that the occurrence of eye disorders may have been related to exposure to BI 409306, is that subjects reported eye disorders at the same time as C max,ss and C max,ss values were higher in subjects reporting eye disorders compared with their counterparts that did not ( Figure S2 ). Although the number of AEs may have been dependent on CYP2C19 genotype, the overall effect of both CYP2C19 genotype and age on safety was minimal. These findings are consistent with those previously reported in two trials investigating single rising doses (0.5-350 mg) and SD (25-200 mg) administration of BI 409306. (Boland et al., 2017; Moschetti et al., 2016) Similar to the present trials, eye disorders were also observed after single rising dose administration of BI 409306, (Moschetti et al., 2016) though in one trial these were only observed at a high dose of BI 409306 (200 mg; chromatopsia in 25% of subjects and blurred vision in 25%) (Boland et al., 2017) .
PK characteristics upon MD are consistent with data obtained after SD in previous studies (Boland et al., 2017; Moschetti et al., 2016) , such that PK was characterised by rapid absorption followed by a rapid monophasic to biphasic elimination in addition to a dose-dependent increase in systemic exposure. Furthermore, a higher exposure was seen in PM of CYP2C19 compared to non-PM across the three multiple dose trials, similar to the 2.2-to 2.3-fold higher C max , and 4.1-to 5.0-fold higher AUC 0-1 in PM vs EM observed in the previous single dose study (Moschetti et al., 2016) .
In these studies, it could be shown however that higher exposure is not necessarily associated with a higher risk of accumulation upon multiple dosing: while the elderly population showed slightly higher exposure versus the young population in Trial 1, and PM of CYP2C19 generally achieved higher plasma concentrations than non-PM at a given dose, these differences were not associated with a delay in reaching SS or higher accumulation ratios. For example, SS was achieved rapidly by Day 2-3 and accumulation was minor in young and elderly subjects, as well as PM and non-PM of CYP2C19.
Due to the small sample size of each subgroup, these findings require confirmation in larger trials. As these were three separate trials, there should be caution when comparing data across the trials.
Conclusions
In young and elderly subjects genotyped as CYP2C19 PM, EM, IM and UM, SD and MD of BI 409306 (25-100 mg) were well tolerated and no safety concerns were identified. PK was characterised by a rapid absorption and elimination with minor accumulation. Overall, the PK profiles were similar in young and elderly subgroups, but systemic exposure was higher in CYP2C19 PM subgroups. However, the impact of these differences on the overall safety profiles was acceptable.
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